Sign in

Travis Fleming

@tjflemin.bsky.social
97 followers 99 following 35 posts

Harvard Medical School PhD '25 @bloodgenes.bsky.social lab Functional genomics, CRISPR screens, Acute Myeloid Leukemia, Drug discovery, targeted protein degradation @danafarber.bsky.social @bostonchildrens.bsky.social @broadinstitute.org

PostsRepliesMedia
Reposted by Travis Fleming
Alexis Caulier @hemagene.bsky.social · 03/04/2025
Out today in @science.org! What if you could chart cells' regulatory programs at unprecedented resolution? In my work with Jorge Martin-Rufino from the @bloodgenes.bsky.social lab, we dissect the genome’s control circuits and find where key genetic variation hides bit.ly/3YhBMoO
bit.ly
Transcription factor networks disproportionately enrich for heritability of blood cell phenotypes
Most phenotype-associated genetic variants map to noncoding regulatory regions of the human genome, but their mechanisms remain elusive in most cases. We developed a highly efficient strategy, Perturb...
45117
Travis Fleming @tjflemin.bsky.social · 06/01/2025
A huge congrats to @dpastoors.bsky.social and @delwelruud.bsky.social for this fantastic work!
120
Reposted by Travis Fleming
Dorien Pastoors @dpastoors.bsky.social · 03/01/2025
Congrats @tjflemin.bsky.social, @bloodgenes.bsky.social and coauthors! I feel like preprint directly ties together #HemeSky 's favorite two transcription factors: MECOM and CEBPA. As to why these two: I'm heavily biased as our complementary work will also be on biorxiv soon (monday!!)
161
Reposted by Travis Fleming
Vijay G. Sankaran @bloodgenes.bsky.social · 02/01/2025
Wonderful to have this work led by @tjflemin.bsky.social along with other colleagues in our laboratory, as well as great collaborators, out on @biorxivpreprint.bsky.social! Stay tuned for exciting complementary work from @dpastoors.bsky.social, Ruud Delwel, and co coming soon!
0225
Travis Fleming @tjflemin.bsky.social · 02/01/2025
Stem cell-like states confer poor outcomes in blood cancer—but what mechanisms drive this and how can they be therapeutically targeted? In our new preprint, we show how a single TF represses one enhancer to maintain a subset of high-risk leukemias: 🧵👇 www.biorxiv.org/content/10.1...
1228
Reposted by Travis Fleming
Vijay G. Sankaran @bloodgenes.bsky.social · 11/12/2024
🙏 🙏 Honored to have the work from @tjflemin.bsky.social from our lab featured in the Best of #ASH24!!!
0222
Travis Fleming @tjflemin.bsky.social · 10/12/2024
Had a blast presenting our work today at #ASH24! Very grateful for my mentors and colleagues for their support. Stay tuned very soon for more on this study on how we’ve functionally dissected high-risk leukemias
1101
Reposted by Travis Fleming
Vijay G. Sankaran @bloodgenes.bsky.social · 09/12/2024
Please come see @tjflemin.bsky.social present on his groundbreaking work at @ash-hematology.bsky.social #ASH24 that reveals a surprisingly simple regulatory logic for high-risk AMLs ... Happening soon in Manchester Grand Hyatt San Diego Seaport Ballrooms ABCD: ash.confex.com/ash/2024/web...
ash.confex.com
Paper: Targeted Protein Degradation Reveals a Repressive Role of Mecom at the <em>CEBPA</Em> Locus to Prevent Differentiation in High-Risk Acute Myeloid Leukemia
083
Reposted by Travis Fleming
Vijay G. Sankaran @bloodgenes.bsky.social · 09/12/2024
#ASH24 Please check out these two abstracts from our laboratory! Travis Fleming will present his talk this afternoon and Alexis Caulier will present his poster this evening!
0124
Travis Fleming @tjflemin.bsky.social · 05/12/2024
Anticipating a hefty hangover from those hot Miami Nights at #ASH24 this weekend? Have no fear! I have the solution. Doctors hate this one trick: 🧵👇
130